Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2014

View Archived Issues

A*STAR partners with Roche in cancer

Merck & Co. patents novel HIV integrase inhibitors

Actelion presents novel P2X7 receptor antagonists

Grant supports DiamiR's work on brain-enriched microRNA biomarkers for Parkinson's disease

Ratiopharm claims new MMF prodrugs

Almirall patents novel dual beta2 agonists and M3 antagonists

Serum peptide signature detects early-stage lung cancer

Gene signature correlated with prognosis in colorectal cancer

Novel agents for cancer and infections reported by the University of Washington

Purdue Pharma patents new Na(v)1.7 channel blockers

C4T discloses new cannabinoid CB2 receptor agonists

Takeda Pharmaceutical discloses novel DAAO inhibitors

Ventrus Biosciences becomes Assembly Biosciences

PharmaMar and Chugai enter into license agreement in Europe for Aplidin

Treatment with PF-05231023 improves lipid parameters in patients with type 2 diabetes

ZS Pharma completes enrollment in second phase III study of ZS-9 in hyperkalemia

Abbott to sell part of generics business to Mylan

AstraZeneca's proton pump inhibitor enters pediatric phase I/II clinical trial

BioChaperone Combo shows promising PK/PD profile in early clinical trials

Novartis collaborates with Banner Alzheimer's Institute on AD prevention study

SBIR grant supports Cel-Sci's development of LEAPS technology for RA

Neos Therapeutics reports phase III findings for NT-0102

FDA grants priority review to sNDA for simeprevir in combination with sofosbuvir

GSK and Theravance initiate phase III program of triple combination treatment for COPD

Nymox completes enrollment in second re-injection study of NX-1207 for BPH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...